Impact of temozolomide on gonadal function in patients with primary malignant brain tumors

Journal of Oncology Pharmacy Practice

Volumn 19, Issue 4, 2013, Pages 321-327

  Strowd, R E ^a   Blackwood, R ^a   Brown, M ^b   Harmon, M ^a   Lovato, J ^a   Yalcinkaya, T ^a   Lesser, G ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b WAKE FOREST BAPTIST HEALTH   (United States)

Author keywords

fertility; Malignant glioma; temozolomide

Indexed keywords

ARSENIC; CARBOXYMETHYLCELLULOSE POLYCYTIDYLIC POLYINOSINIC ACID POLYLYSINE; CARMUSTINE; FOLLITROPIN; LUTEINIZING HORMONE; TEMOZOLOMIDE; TESTOSTERONE; VINCRISTINE;

ADULT; ARTICLE; ASTROCYTOMA; BRAIN CANCER; BRAIN RADIATION; CANCER RADIOTHERAPY; CLINICAL ARTICLE; GLIOBLASTOMA; GLIOSARCOMA; GONAD DYSFUNCTION; GONAD FUNCTION; HUMAN; IMPOTENCE; MALE; MULTIPLE CYCLE TREATMENT; OLIGODENDROGLIOMA; PILOT STUDY; PRIORITY JOURNAL; SEMEN ANALYSIS; SPERM; SPERMATOZOON DENSITY; SPERMATOZOON MOTILITY;

FERTILITY; MALIGNANT GLIOMA; TEMOZOLOMIDE;

ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; COMBINED MODALITY THERAPY; DACARBAZINE; FOLLOW-UP STUDIES; GLIOMA; GONADAL STEROID HORMONES; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PILOT PROJECTS; PROSPECTIVE STUDIES; SEMEN; SPERM MOTILITY; TIME FACTORS;

EID: 84879808855     PISSN: 10781552     EISSN: 1477092X     Source Type: Journal    
DOI: 10.1177/1078155212469243     Document Type: Article

References (26)

1. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006 ; 24: 2917-2931
2. Meistrich ML, Vassilopoulou-Sellin R, Lipshultz LI Cancer: principles and practice of oncology. 7 th ednPhiladelphia, PA: Lippincot Raven Press, 2005, 2560-2572. DeVita VT Hellman S Roseberg SA, ed. Philadelphia, PA: Lippincot Raven Press ; 2005: 2560-2572.
3. Drasga RE, Einhorn LH, Williams SD, et al. Fertility after chemotherapy for testicular cancer. J Clin Oncol. 1983 ; 1: 179-183
4. Pryzant RM, Meistrich ML, Wilson G, et al. Long-term reduction in sperm count after chemotherapy with and without radiation therapy for non-Hodgkin's lymphomas. J Clin Oncol. 1993 ; 11: 239-247
5. Marmor D, Duyck F. Male reproductive potential after MOPP therapy for Hodgkin's disease: a long-term survey. Andrologia. 1995 ; 27: 99-106
6. Meistrich ML. Critical components of testicular function and sensitivity to disruption. Biol Reprod. 1986 ; 34: 17-28
7. Meistrich ML. Relationship between spermatogonial stem cell survival and testis function after cytotoxic therapy. Br J Cancer. 1986 ; 53: 89-101
8. Pera MF, Köberle B, Masters JR. Exceptional sensitivity of testicular germ cell tumour cell lines to the new anti-cancer agent, temozolomide. Br J Cancer. 1995 ; 71: 904-906
9. Hansen S, Berthelsen J, von der Maase H. Long-term fertility and Leydig cell function in patients treated for germ cell cancer with cisplatin, vinblastine and bleomycin versus surveillance. J Clin Oncol. 1990 ; 8 (10). 1695-1698
10. Gaffan J, Holden L, Newlands ES, et al. Infertility rates following POMB/ACE chemotherapy for male and female germ cell tumours - a retrospective long-term follow-up study. Br J Cancer. 2003 ; 89 (10). 1849-1854
11. Kangasniemi M, Huhtaniemi I, Meistrich ML. Failure of spermatogenesis to recover despite the presence of spermatogonia in the irradiated LBNF1 rat. Biol Reprod. 1996 ; 54: 1200-1208
12. Roeser HP, Stocks AE, Smith AJ. Testicular damage due to cytotoxic and recovery after cessation of therapy. Aust N Z J Med. 1978 ; 8: 250-254
13. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered?. Lancet Oncol. 2005 ; 6 (4). 209-218
14. Colvin DM. Alkylating agents and platinum antitumor compounds. In: Bast RC, Kufe DW, Pollock RE, et al. (eds) Cancer medicine. 5th edn. Hamilton, ON: BC Decker Inc., Ch 48, 2000, pp.648-669.
15. Rhoads CP. Nitrogen mustards in treatment of neoplastic disease. JAMA. 1946 ; 131: 656-658
16. Whitehead E, Shalet SM, Jones PH, et al. The effects of Hodgkin's disease and combination chemotherapy on gonadal function in the adult male. Cancer. 1982 ; 49: 418-422
17. Friedman HS, Kerby T, Calvert H. Temozolomide and treatment of malignant glioma. Clin Cancer Res. 2000 ; 6: 2585-2597
18. Physicians' desk reference. 56 th edn, Montvale, NJ: Medical Economics Company, 2002. Montvale, NJ: Medical Economics Company ; 2002 :
19. Palmieri C, Brock C, Newlands ES. Maintenance of fertility following treatment with temozolomide for a high grade astrocytoma. J Neurooncol. 2005 ; 73 (2). 185-185
20. Kumar SG, Narayana K, Bairy KL, et al. Dacarbazine induces genotoxic and cytotoxic germ cell damage with concomitant decrease in testosterone and increase in lactate dehydrogenase concentration in the testis. Mutat Res. 2006 ; 607: 240-252
21. Viviani S, Ragni G, Santoro A, et al. Testicular dysfunction in Hodgkin's disease before and after treatment. Eur J Cancer. 1991 ; 27: 1389-1392
22. Wong WY, Thomas CM, Merkus JM, et al. Male factor subfertility: possible causes and the impact of nutritional factors. Fertil Steril. 2000 ; 73: 435-442
23. Costabile RA, Spevak M. Cancer and male factor infertility. Oncology (Williston Park). 1998 ; 12: 557-570
24. Sabanegh E, Ragheb A. Male fertility after cancer. Urology. 2009 ; 73 (2). 225-231
25. Littley M, Shalet S, Beardwell C, et al. Radiation-induced hypopituitarism is dose-dependent. Clin Endocrinol. 1989 ; 31 (3). 363-373
26. Wallace E, Groome N, Riley S, et al. Effects of chemotherapy-induced testicular damage on inhibin, gonadotropin, and testerosterone secretion: a prospective longitudinal study. J Clin Endocrinol Metab. 1997 ; 82: 3111-3115